Exchange: NYSEArca·Updated 04:15 PM EST

XPH News

News
all
press releases
More News
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
Zacks
Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.
Zacks
H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.
Stocktwits
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
Stocktwits
Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.
Stocktwits

Advertisement|Remove ads.